BACKGROUND: Trihalomethanes (THMs) are widespread disinfection by-products (DBPs) in drinking water, and long-term exposure has been consistently associated with increased bladder cancer risk. OBJECTIVE: We assessed THM levels in drinking water in the European Union as a marker of DBP exposure and estimated the attributable burden of bladder cancer. METHODS: We collected recent annual mean THM levels in municipal drinking water in 28 European countries (EU28) from routine monitoring records. We estimated a linear exposure–response function for average residential THM levels and bladder cancer by pooling data from studies included in the largest international pooled analysis published to date in order to estimate odds ratios (ORs) for bladder cancer associated with the mean THM level in each country (relative to no exposure), population-attributable fraction (PAF), and number of attributable bladder cancer cases in different scenarios using incidence rates and population from the Global Burden of Disease study of 2016. RESULTS: We obtained 2005–2018 THM data from EU26, covering 75% of the population. Data coverage and accuracy were heterogeneous among countries. The estimated population-weighted mean THM level was 11:7 μg/L [standard deviation (SD) of 11.2]. The estimated bladder cancer PAF was 4.9% [95% confidence interval (CI): 2.5, 7.1] overall (range: 0–23%), accounting for 6,561 (95% CI: 3,389, 9,537) bladder cancer cases per year. Denmark and the Netherlands had the lowest PAF (0.0% each), while Cyprus (23.2%), Malta (17.9%), and Ireland (17.2%) had the highest among EU26. In the scenario where no country would exceed the current EU mean, 2,868 (95% CI: 1,522, 4,060; 43%) annual attributable bladder cancer cases could potentially be avoided. DISCUSSION: Efforts have been made to reduce THM levels in the European Union. However, assuming a causal association, current levels in certain countries still could lead to a considerable burden of bladder cancer that could potentially be avoided by optimizing water treatment, disinfection, and distribution practices, among other possible measures.

Trihalomethanes in drinking water and bladder cancer burden in the European Union / Evlampidou, I.; Font-Ribera, L.; Rojas-Rueda, D.; Gracia-Lavedan, E.; Costet, N.; Pearce, N.; Vineis, P.; Jaakkola, J. J. K.; Delloye, F.; Makris, K. C.; Stephanou, E. G.; Kargaki, S.; Kozisek, F.; Sigsgaard, T.; Hansen, B.; Schullehner, J.; Nahkur, R.; Galey, C.; Zwiener, C.; Vargha, M.; Righi, E.; Aggazzotti, G.; Kalnina, G.; Grazuleviciene, R.; Polanska, K.; Gubkova, D.; Bitenc, K.; Goslan, E. H.; Kogevinas, M.; Villanueva, C. M.. - In: ENVIRONMENTAL HEALTH PERSPECTIVES. SUPPLEMENTS. - ISSN 2169-2181. - 128:1(2020), pp. 1-17001. [10.1289/EHP4495]

Trihalomethanes in drinking water and bladder cancer burden in the European Union

Righi E.;Aggazzotti G.;
2020

Abstract

BACKGROUND: Trihalomethanes (THMs) are widespread disinfection by-products (DBPs) in drinking water, and long-term exposure has been consistently associated with increased bladder cancer risk. OBJECTIVE: We assessed THM levels in drinking water in the European Union as a marker of DBP exposure and estimated the attributable burden of bladder cancer. METHODS: We collected recent annual mean THM levels in municipal drinking water in 28 European countries (EU28) from routine monitoring records. We estimated a linear exposure–response function for average residential THM levels and bladder cancer by pooling data from studies included in the largest international pooled analysis published to date in order to estimate odds ratios (ORs) for bladder cancer associated with the mean THM level in each country (relative to no exposure), population-attributable fraction (PAF), and number of attributable bladder cancer cases in different scenarios using incidence rates and population from the Global Burden of Disease study of 2016. RESULTS: We obtained 2005–2018 THM data from EU26, covering 75% of the population. Data coverage and accuracy were heterogeneous among countries. The estimated population-weighted mean THM level was 11:7 μg/L [standard deviation (SD) of 11.2]. The estimated bladder cancer PAF was 4.9% [95% confidence interval (CI): 2.5, 7.1] overall (range: 0–23%), accounting for 6,561 (95% CI: 3,389, 9,537) bladder cancer cases per year. Denmark and the Netherlands had the lowest PAF (0.0% each), while Cyprus (23.2%), Malta (17.9%), and Ireland (17.2%) had the highest among EU26. In the scenario where no country would exceed the current EU mean, 2,868 (95% CI: 1,522, 4,060; 43%) annual attributable bladder cancer cases could potentially be avoided. DISCUSSION: Efforts have been made to reduce THM levels in the European Union. However, assuming a causal association, current levels in certain countries still could lead to a considerable burden of bladder cancer that could potentially be avoided by optimizing water treatment, disinfection, and distribution practices, among other possible measures.
2020
15-gen-2020
128
1
1
17001
Trihalomethanes in drinking water and bladder cancer burden in the European Union / Evlampidou, I.; Font-Ribera, L.; Rojas-Rueda, D.; Gracia-Lavedan, E.; Costet, N.; Pearce, N.; Vineis, P.; Jaakkola, J. J. K.; Delloye, F.; Makris, K. C.; Stephanou, E. G.; Kargaki, S.; Kozisek, F.; Sigsgaard, T.; Hansen, B.; Schullehner, J.; Nahkur, R.; Galey, C.; Zwiener, C.; Vargha, M.; Righi, E.; Aggazzotti, G.; Kalnina, G.; Grazuleviciene, R.; Polanska, K.; Gubkova, D.; Bitenc, K.; Goslan, E. H.; Kogevinas, M.; Villanueva, C. M.. - In: ENVIRONMENTAL HEALTH PERSPECTIVES. SUPPLEMENTS. - ISSN 2169-2181. - 128:1(2020), pp. 1-17001. [10.1289/EHP4495]
Evlampidou, I.; Font-Ribera, L.; Rojas-Rueda, D.; Gracia-Lavedan, E.; Costet, N.; Pearce, N.; Vineis, P.; Jaakkola, J. J. K.; Delloye, F.; Makris, K. C.; Stephanou, E. G.; Kargaki, S.; Kozisek, F.; Sigsgaard, T.; Hansen, B.; Schullehner, J.; Nahkur, R.; Galey, C.; Zwiener, C.; Vargha, M.; Righi, E.; Aggazzotti, G.; Kalnina, G.; Grazuleviciene, R.; Polanska, K.; Gubkova, D.; Bitenc, K.; Goslan, E. H.; Kogevinas, M.; Villanueva, C. M.
File in questo prodotto:
File Dimensione Formato  
Evlampidou EHP 2020 EU THMs & bladder cancer.pdf

Open access

Descrizione: articolo
Tipologia: Versione pubblicata dall'editore
Dimensione 512.86 kB
Formato Adobe PDF
512.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1203302
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 81
social impact